When a THC Hair Screen Is Positive but Confirmation Is Negative
A positive THC hair screen requires scrutiny when the assay fails to distinguish confirmed positive and negative specimens. A 2026 evaluation of the SAMElife screening kit illustrates why performance for other drugs cannot be transferred automatically to the cannabinoid component.
What was tested
Martini and colleagues evaluated 31 anonymized hair specimens across several drug categories, comparing screening results with GC–MS or LC–MS/MS confirmation. A subset of 15 specimens was additionally evaluated for THC. These were laboratory specimens, not a controlled cannabis-administration study or a test of present impairment.
The THC result differed from the other results
The basic-drug panel showed high specificity, although cocaine false negatives occurred. THC screening performed poorly: the tested specimens were uniformly positive despite confirmation showing that only a minority were positive. The favorable performance figures for the basic drugs therefore cannot honestly be presented as the accuracy of this THC assay.
A platform may perform differently for different analytes because the antibodies, target concentrations, matrix interactions, and extraction problems differ. Reporting one overall accuracy number can conceal the failure most relevant to the case.
What the study cannot establish
The small, selected sample is not a representative survey of every hair laboratory or every cannabinoid immunoassay. It cannot supply a universal false-positive rate. Nor does it establish why any particular person’s screening result was positive. The source also contains differing descriptions of decontamination in its methods and discussion, making the preparation records especially important rather than resolving that uncertainty by assumption.
How to examine a disputed result
Obtain the assay identity and lot, sample preparation record, screening cutoff, quality controls, and actual confirmatory result. Identify the compound confirmed, its reporting limit, and the method’s ability to distinguish relevant analytes. A statement that a sample was “tested” is insufficient if it conceals a screen that was never confirmed.
Even a properly confirmed hair finding does not, by itself, demonstrate impairment at a particular event. The immediate question in a discordant case is narrower: which analytical result supports the claimed identification, and how was the disagreement resolved?
Related evidence
See our related analysis of toxicology evidence and its limits.
Primary research
Evaluation of a rapid immunoenzymatic screening kit (SAMElife™) for drugs of abuse detection in hair. Journal of Analytical Toxicology, 2026. DOI: 10.1093/jat/bkag053.
